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Should Anti-Tumor Necrosis Factor−α Be the First Therapy
for Rheumatoid Vasculitis?
To the Editor:
The risk of vasculitis following tumor necrosis factor-α (TNF-α) blockade
remains controversial1-3. In 2002, we reported a successful response to the
chimeric anti-TNF-α monoclonal antibody infliximab in a patient with
biopsy-proved rheumatoid vasculitis presenting with mononeuritis multi-
plex who was refractory to cyclophosphamide (CYC)4.
High-dose steroid and intravenous CYC are the cornerstone therapy in
rheumatoid vasculitis5. However, CYC is potentially associated with the
development of ominous side effects6, and in some cases this therapy does
not result in improvement of the vasculitis4,5.
Anti-TNF-α therapy is indicated in rheumatoid arthritis (RA) patients
with severe and refractory disease7. In our unit we have recently estab-
lished a protocol for the management of RA patients with rheumatoid vas-
culitis using anti-TNF therapy instead of intravenous CYC. Following this
procedure, we had the opportunity of treating a 73-year-old man who
developed foot drop. He had a seropositive and erosive RA of 25 years’
duration treated with several disease modifying antirheumatic drugs,
including methotrexate and more recently leflunomide. One month before
admission he began to notice weakness of his right foot. On examination,
paresis on dorsiflexion of the right foot was found. Erythrocyte sedimenta-
tion rate was 85 mm/h. Chest radiograph and routine biochemistry profile
including renal and hepatic function tests, antinuclear antibodies, anti-
native DNA, C3 and C4, and anticardiolipin antibodies were negative or
normal. Electromyography result was consistent with mononeuritis multi-
plex, and biopsy of the right sural nerve showed focal and segmental necro-
tizing arteritis of small and medium-size arteries with fibrinoid necrosis
and neutrophil infiltration in the artery wall. He was diagnosed as having
rheumatoid vasculitis. Therapy with leflunomide was discontinued.
Treatment with methotrexate (15 mg/week) was restarted and anti-TNF-α
monoclonal antibody (infliximab) therapy was started. Infusion of inflix-
imab at a dose of 3 mg/kg body weight was administered according to the
standard protocol of therapy (at Weeks 0, 2, 6, and 14 and then every 8
weeks). Again, as described3,4, 6 weeks after the initiation of infliximab
therapy the motor dysfunction had regressed markedly.
Taken together, all these reports support the potential use of anti-TNF-
α therapy in the treatment of neuropathy associated with rheumatoid vas-
culitis. However, in keeping with Richette, et al1, a prospective controlled
study should be performed to confirm the promising results observed so
far.
CARLOS GARCIA-PORRUA, MD, PhD; MIGUEL A. GONZALEZ-
GAY, MD, PhD, Rheumatology Division, Hospital Xeral-Calde; VICTOR
QUEVEDO, MD, Rheumatology Division, Hospital Comarcal Monforte,
Monforte de Lemos, Lugo, Spain. 
E-mail: cgporrua@hotmail.com
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Dr. Richette and Dr. Bardin reply
To the Editor:
We read with interest the letter from Dr. Garcia-Porrua and colleagues
describing another case of successful treatment of rheumatoid vasculitis-
associated mononeuritis with infliximab. The authors use anti-TNF-α
blockers as a first-line therapy instead of intravenous cyclophosphamide to
treat patients with rheumatoid vasculitis. Some clinicians have previously
reported the efficacy of TNF-α-blocking therapy during rheumatoid vas-
culitis1,2.
By contrast, we and others have observed cutaneous3, neurological4,5,
or antineutrophil cytoplasmic autoantibody-related6 vasculitis induced by
anti-TNF-α agents. In this context, the use of TNF-α blockers during
rheumatoid vasculitis may be hazardous. Although the scientific interest of
a single case observation is of limited value, it may alert us to potential side
effects. We need a definitive controlled trial to ascertain the efficacy of
anti-TNF-α agents to treat rheumatoid vasculitis.
PASCAL RICHETTE, MD, PhD; THOMAS BARDIN, MD, Fédération
de Rhumatologie, Centre Viggo Petersen, Hôpital Lariboisière, 2 rue
Ambroise Paré, Paris, France. E-mail: pascal.richette@lrb.ap-hop-paris.fr
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Definition of Clinical Differences
To the Editor:
The article by Wolfe, et al1 compares the mean scores on the Health
Assessment Questionnaire (HAQ) and the Physical Component Scores
(PCS) of the Short Form-36 (SF-36) in different patient groups, using 6 dif-
ferent anchors to define these groups. The mean difference found between
these groups is called Really Important Differences (RID). They chose as
anchors for determining RID several clinical and societal outcomes, such
as independence in participation activities versus not, or total joint replace-
ment versus no total joint replacement. In this way they attach meaningful
anchors to scores on the HAQ and the PCS of the SF-36. This is a very use-
ful contribution to the interpretation of scores on the HAQ-DI and PCS by
clinicians and patients. We would like to comment on 2 points.
Extrapolation of group differences to individual changes. We criticize the
extrapolation of their cross-sectional findings about differences between
groups to improvements in individual patients in randomized controlled tri-
als (RCT) or clinical practice. First, the authors make no distinction
between really important difference (RID) and really important change
(RIC). They use these concepts interchangeably, which leads to confusion.
An illustrative example appears in their Table 2: patients without a total
joint replacement have more favorable scores on the HAQ and PCS than
patients with a total joint replacement. This would suggest that surgery to
replace a joint leads to deterioration of health. This shows that “really
important change” cannot be derived directly from “really important dif-
ference.” RID considers the differences between (groups of) individuals,
while important improvements refer to changes within (groups of) individ-
uals. To assess RID, different groups of patients are compared cross-sec-
tionally, while RIC concerns intra-individual changes, which are assessed
longitudinally by following the same individuals over time.
Second, Wolfe, et al present the mean scores and standard deviations
(SD) on the HAQ and PCS of the SF-36 for different groups of patients. All
SD are rather large, which means that there are substantial differences
between patients. Consider for instance a patient scoring 0.80 on the HAQ,
exactly the mean score of patients who are not work-disabled (Table 2 of
Wolfe, et al). Is it safe to assume that this patient is really able to work?
Not at all, as the 95% confidence interval of the work-disabled patients
runs from 0.32 to 2.78 (i.e., 1.55 ± 1.96*0.63), provided the scores are nor-
mally distributed. It is obvious that a given work-disabled patient does not
necessarily have to experience a “really important” improvement of 0.74
points (100% of RID) on the HAQ in order to regain the ability to work. In
fact, in individual cases the necessary improvement, in terms of HAQ score
change, may be smaller or much larger. Therefore, one should be cautious
in extrapolating these group findings to individual patients. 
Objections against the minimal clinically important difference (MCID).
The authors point out a number of objections to MCID, which are in their
opinion not encountered by defining RID. As we do not agree with any of
these, we will react to them one by one.
Wolfe, et al state that “MCID represents a minimally clinically impor-
tant (or detectable) change, which may be neither clinically meaningful nor
useful.” This objection has to do with the fact that they consider the MCID
to be synonymous with the minimally detectable difference. They state that
“A widely adopted approach for defining meaningful change is to identify
the minimally clinically important difference (MCID), or the minimal
detectable improvement perceptible to patients.” However, the widely
adopted definition of Jaeschke, et al2 for MCID being “the smallest differ-
ence in score in the domain of interest which the patients perceive as ben-
eficial and which would mandate, in the absence of troublesome side-
effects and excessive cost, a change in the patient’s management,” clearly
points to the importance of the change for patients and/or importance for
clinical management. Note that in this definition MCID concerns a clini-
cally meaningful change, and it does not contain any reference to what is
minimally detectable2.
Furthermore, Wolfe, et al see the dependence of MCID on baseline val-
ues as a disadvantage. However, this dependence is real and functional. For
instance, if “independence in participation” is considered to be an impor-
tant goal, patients who are close to this value need a smaller change than
those patients whose baseline values are far from that intended score. This
also holds for really important changes or differences.
As second objection, Wolfe, et al mention that “as MCID identifies a
minimal detectable improvement rather than deterioration, it is not possi-
ble to interpret the magnitude of change patients perceive to be important.”
MCID might focus on improvements and deteriorations separately, and
various studies have shown that these do not need to be the same3.
Typically, Wolfe, et al determine “real important differences” instead of
“real important changes” as they perform a cross-sectional analysis.
Intuitively, one would say that the magnitude of “important differences”
will be the same as magnitudes of “important changes.” The example of
total joint replacement shows that this is not true. In addition, the fact that
minimally clinically important change (MCIC) for improvement and
MCIC for deterioration sometimes differ, clearly implies that “important
differences” are not the same as “important changes.” Note that this holds
for both MCID and RID.
Wolfe, et al state that “When applied to RCT, it is not always clear
whether MCID should refer to absolute change from baseline or if one
should subtract the result of placebo or comparator treatment.” Often in
RCT differences in change in different arms are determined. Using MCIC,
one might report the percentage of patients showing a change larger than
the MCIC value in each treatment arm (success rate), and analyze whether
these percentages differ significantly between the arms. For RID, Wolfe, et
al propose to express the results in percentage of RID achieved in each
arm. Also in this case one should take the decision to refer to absolute
change from baseline or subtract the result of placebo or comparator treat-
ment.
Wolfe, et al state that “MCID does not offer clinicians an appropriate
goal for improvement, based on patient’s perceptions of realistic and desir-
able HAQ-DI or SF-36 PCS scores.” We do not agree with this statement.
In our opinion, MCID and MCIC values are far more realistic than RID
values. One important point is that the large differences reported in this
cross-sectional study may not be attainable (any more) for most patients
thinking about improvement. This is illustrated by the fact that Wolfe, et al
suggest expression of the change as a percentage of RID in RCT and clin-
ical practice.
As a last objection, Wolfe, et al state that it is not clear how definitions
of MCID should be used to interpret results from RCT or applied to clini-
cal practice. In our opinion the MCID or MCIC defines the boundary
between success and failure. The analysis of RCT as described above, com-
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paring the percentages of patients that reach the MCIC or MCID in both
treatment arms, is a very realistic approach. The ways in which MCID and
RID are applied are the same in this respect. 
In summary, in our opinion the RIC is a subclass of MCIC concerning
the extreme situation that patients perceive only large changes as minimal-
ly important. The OMERACT group4 has presented a cube with 3 dimen-
sions that are all at issue in this report: a dimension indicating change or
difference, a dimension indicating group or individual level, and a dimen-
sion indicating the type of difference/change being assessed. In the latter
they distinguish minimum potentially detectable, minimum actually
detectable beyond error, observed in a population, observed in those esti-
mated to differ/to have changed, and observed in those estimated to have
an important difference/change. Information about all these anchors on the
scale of a measurement helps to interpret the (change in) scores.
We would plead for rehabilitation of the term MCIC (not MCID) as a
change that patients would consider important to reach in their situation,
dependent on baseline values or severity of disease, on the type of inter-
vention, and on the duration of the followup period. This MCIC value
would be an important parameter to be used in power calculations in the
design of clinical studies.
HENRICA C.W. de VET; HELEEN BECKERMAN; CAROLINE B.
TERWEE; BEREND TERLUIN, MD, and LEX M. BOUTER, for the
Clinimetrics Working Group, VU University Medical Center, Amsterdam,
The Netherlands. E-mail: hcw.devet@vumc.nl
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Dr. Wolfe, et al reply
To the Editor:
We would like to address issues raised by de Vet, et al. We must first note
that in many areas of contention they have inferred uses, methods, and con-
clusions regarding MCID and RID that we neither suggested nor intended
in our article.
We have no argument with the authors’ preferences for the term MCIC;
however, we would point out that Medline and Google Scholar searches for
the abbreviated and unabbreviated term produced 22 MCIC citations com-
pared with more than 500 citations for MCID. When we described mean-
ingful change as MCID or the minimal detectable improvement percepti-
ble to patients we were not endorsing the terminology, but were using
inclusive terms that had considerable prior use and that might be under-
stood by readers.
We did not suggest the conjunction of grouped data and patient level
data. In fact, we have recently warned against the use of grouped data at
the patient level1. Instead, we suggested standards and measuring posts that
were based on grouped data that could be used in understanding grouped
data results that come from clinical trials. In these recommendations the
standard deviations of the HAQ/SF-36 are immaterial.
De Vet, et al have problems with our application of between-patient
differences seen in observational data to within-patients changes observed
in clinical trials. We have no such problem, as our purpose was only to
describe endpoints that might be used to interpret clinical trials; endpoints
such as work disability and total joint replacement are crucial in rheuma-
toid arthritis (RA) but can never be observed in clinical trials because of
the length of time required to reach such endpoints. Where de Vet, et al see
inconsistencies in results, we see examples that provide clinical guidance,
an approach to clinical outcomes that adds meaning to statistical differ-
ences and change.
The thesis of de Vet, et al that MCIC should represent “change that
patients would consider important to reach [and is] dependent on baseline
values or severity of disease, on the type of intervention, and on the dura-
tion of the followup period,” is one with which we agree. The authors have
stated this more clearly elsewhere2: “The MCIC should not be considered
as a fixed value, ...the exact value for the MCIC can be determined, taking
into account the aim of the measurement, the initial scores, the target pop-
ulation and the method used to assess MCIC.” The problem with this rep-
resentation, however, is that there is only one known MCID/MCIC for the
HAQ (or SF-36) in RA, a value that does not account for baseline values.
We are unaware of any current method in RA to determine the proper
MCID/MCIC for HAQ/SF-36 that incorporates baseline values or disease
severity.
A signal problem with the MCID concept as it applies to functional
measurements in RA is not only that the functional outcomes are longterm
and beyond the scope of a clinical trial, but that they cannot be measured
in the HAQ or SF-36 units of the clinical trial. Instead, the outcomes of
interest are work disability, total joint replacement, impoverishment, and
mortality. The differences in rates of these outcomes that we have
described serve to put into a clinically useful perspective changes that are
reported in clinical trials because they allow changes to be placed into the
perspective of clinically useful outcomes. In addition, our data address the
most important aspect of RA outcome, functional status, rather than change
in status. A HAQ change of 0.25 may represent a MCIC for the patient with
a HAQ score of 0.5 as well as for a patient with a HAQ score of 2.5. But
no one should mistake the difference between these 2 patients.
FRED WOLFE, MD, Arthritis Research Center Foundation, University of
Kansas School of Medicine, Wichita, Kansas; KALEB MICHAUD, MS,
Center for Primary Care and Outcomes Research, Stanford University
School of Medicine; VIBEKE STRAND, MD, Division of Immunology,
Stanford University School of Medicine, Stanford, California, USA. 
E-mail: fwolfe@arthritis-research.org
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Antibodies to Cyclic Citrullinated Peptides in Psoriatic
Arthritis: Do Classification Criteria Affect Study Results?
To the Editor:
We read with interest the article concerning the presence of antibodies to
cyclic citrullinated peptides (CCP)1 and as we are performing a similar
study of a population from virtually the same geographical area, we would
like to describe our interim data and make some comments.
Our aim is to establish the usefulness of anti-CCP antibodies in dis-
criminating psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Our
inclusion criteria were the same as those used by Bogliolo, et al1: consec-
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utive outpatients with a diagnosis of PsA according to Moll and Wright2.
As this definition leaves it up to the researcher to decide whether or not to
include cases positive for rheumatoid factor (RF), its specificity depends
on how patients with RA with concomitant psoriasis are ruled out. In our
study, patients with RA with psoriasis and RF-positive patients with true
PsA were distinguished on the basis of an expert’s opinion. More precise-
ly, the patients with features characteristic of RA (rheumatoid nodules, vas-
culitis, typical RA radiographic changes) were excluded from the study,
whereas RF-positive patients with features characteristic of PsA (dactylitis,
distal interphalangeal involvement, axial involvement, and typical PsA
radiographic changes) were included. Anti-CCP antibodies were measured
in sera using a commercially available second generation ELISA kit
(INOVA kit, Quantalite Ltd. San Diego, CA, USA), for which the upper
normal limit suggested by the manufacturer is 20 UI/ml.
We have so far enrolled 129 patients with PsA whose main demo-
graphic and clinical characteristics are shown in Table 1. At the threshold
value of 20 UI/ml, only 4 (3.5%) patients were anti-CCP positive, with
serum levels of 32, 43, 126, and 159 UI/ml. Six patients had anti-CCP val-
ues of 10-20 UI/ml, and the remaining 119 values were < 10 UI/ml. All
anti-CCP positive patients had polyarticular disease, and no correlation
was found between the presence and titer of these antibodies and the mark-
ers of disease severity (number of irreversibly damaged joints, erosive dis-
ease, disability as measured by the Health Assessment Questionnaire, and
therapy with disease modifying antirheumatic agents). Interestingly, the 35
patients (27.1%) in our series who were positive for RF (> 20 UI/ml)
included the 2 patients with the highest anti-CCP values.
In the study by Bogliolo, et al1, 16 out of 102 (15.7%) patients with
PsA were positive for anti-CCP antibodies, a significantly higher percent-
age than we found (p ≤ 0.001 by Fisher’s exact test). All positive values
were > 40 UI/ml, indicating that the large number of positive anti-CCP
cases was not due to an exceedingly low normal limit (5 UI/ml). Finally,
the median positive anti-CCP value was higher in Bogliolo’s study popula-
tion than ours: > 100 UI/ml versus 84 UI/ml, respectively.
Comparison of the 2 studies reveals significant differences in the num-
ber of patients with PsA with a positive anti-CCP test (15.7% vs 3.5%),
which is unlikely to have been due to mere chance because the patients
were comparable in terms of ethnicity, demographics, the main clinical fea-
tures (Table 1), and the level of the attended center (both tertiary). There
are 2 reasonable explanations: a difference in the sensitivity of the tests
and/or the inclusion of patients with RA and concomitant psoriasis. The
first possibility cannot be verified (the same sera should be evaluated by
both tests) but seems to be quite remote as both studies used second-gen-
eration enzyme-linked assays; a misclassification of some patients appears
to be much more likely. It has been shown that Moll and Wright’s defini-
tion of PsA is sensitive and specific when RF-positive cases are excluded3,
but it clearly loses part of its specificity if they are included. Bogliolo, et al1
stated that only 6 out of the 16 anti-CCP positive patients had unmistakable
evidence of PsA, while the remaining patients could have had RA coexist-
ing with psoriasis, thus confirming the relative lack of specificity of diag-
nosis. We used the same diagnostic definition in our study, but also classi-
fied the patients as having PsA only if RA could be reasonably ruled out on
sound clinical and radiographic grounds. In this regard, as about 27% of the
patients were RF positive, our expert considered that this positivity had poor
discriminant value. Comparison of the 2 studies seems to indicate that this
is a classical case of a difference in inclusion criteria leading to a significant
difference in results, which is very important when the sensitivity and speci-
ficity of a new test in a specific rheumatic disorder are still unknown.
The main conclusion we can draw is that great attention needs to be
paid to diagnostic/classification criteria when performing this kind of
study. In the case of PsA, the relative confusion generated by the existence
of at least 7 sets of classification criteria3 should be reduced by the recent
proposal of new criteria4. Another possible conclusion is that it is indeed
virtually impossible to discriminate PsA and RA in a few cases. The coex-
istence of PsA and RA may have played a role but only in a few cases
because, given the approximately 1% prevalence of RA, mere chance
would have meant that only one of Bogliolo’s 102 patients with PsA should
have had coexisting RA. Finally, whether anti-CCP antibodies will be as
helpful in predicting disease severity in PsA as in RA5 will depend on their
true frequency in PsA.
ANTONIO MARCHESONI, MD; ALFREDOMARIA LURATI, MD;
FRANCESCA DESIATI, MD; VALERIA ROSSI, MD; NORMA
BATTAFARANO, MD, Rheumatology Department, G. Pini Orthopedic
Institute, University of Milan, Via Pini 9, 20122 Milan, Italy. Address
reprint requests to Dr. Marchesoni.
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Dr. Bogliolo, et al reply
To the Editor:
We are grateful to Dr. Marchesoni and colleagues for their interest in our
study and for their data so nicely reported. We think some additional com-
ments are required to compare results of the 2 studies.
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Table 1. Main demographic and clinical characteristics of 129 study
patients with PsA. Values are number of patients (%), unless otherwise
indicated.
Variable
Median age, yrs (mean ± SEM) 54 (54 ± 1.4)
Median arthritis duration, yrs (mean ± SEM) 11 (12.3 ± 1)
Median psoriasis duration, yrs (mean ± SEM) 16 (18 ± 1.3)
Males/females 81/48
Mono-oligoarthritis 43 (33)
Polyarthritis 83 (64)
Axial predominant 2 (2.5)
Exclusive DIP involvement 1 (1.2)
Mutilans 11 (8.7)
Axial involvement (all patients) 62 (48.1)
Dactylitis 62 (48.7)
Enthesitis 36 (28)
Damaged joints (mean ± SEM) 3 (5.3 ± 0.9)
Erosive arthritis 100 (77.8)
DMARD therapy 78 (60)
RF positive 35 (26)
CCP positive (> 20 U/ml) 4 (3.1)
CCP median value, U/ml (mean ± SEM) 4.5 (7.9 ± 1.5)
DIP: distal interphalangeal; DMARD: disease modifying antirheumatic
drug.
First of all the aims of the studies are different: while Marchesoni, et al
try to establish the usefulness of anti-cyclic citrullinated peptide (CCP)
antibodies in discriminating psoriatic arthritis (PsA) and rheumatoid arthri-
tis (RA), our study1 focused on the clinical characterization of anti-CCP
positive patients with PsA.
As stated1, we included in our study all patients with idiopathic
arthritis and psoriasis, according to Moll and Wright2, without any addi-
tional exclusion criteria. Of course, a number of patients with RA and
psoriasis may have been included3. However we think that a single
expert’s opinion may be questionable as an inclusion/exclusion criterion
and may be less reproducible than a definite set of criteria4. We agree
with Dr. Marchesoni in that patients with clear clinical and radiograph-
ic evidence of RA do have RA; however, some patients may present with
signs and symptoms typical of both disorders. Moreover, since the anti-
CCP assay has become very popular, we wonder how the expert’s opin-
ion might have been influenced by a positive test for anti-CCP.
Dr. Marchesoni and colleagues state that Moll and Wright’s clas-
sification has proven to be sensitive and specific when RF positive
cases are excluded; however RF positivity was considered to have
poor discriminating value in their study. Surprisingly enough, their
approach in determining true PsA, based on their expert ruling out
RA, led to the highest frequency of RF positive patients reported in
PsA so far1,5. 
It would be interesting to know how many patients fulfilling Moll and
Wright’s criteria were excluded, as well as the clinical picture and autoan-
tibody profile of these patients. A careful analysis of these patients might
be useful to support the need for the expert’s opinion as an additional cri-
terion and the usefulness of anti-CCP antibodies, rather than RF, in dis-
criminating PsA and RA. 
We hope the efforts of Dr. Marchesoni will lead to a suitable set of true
diagnostic criteria for PsA in the near future6. At present, however, we
think that a pragmatic approach to the selection of patients for clinical stud-
ies involves looking for prognostic factors (and we feel that anti-CCP anti-
bodies may be among them) according to widely accepted classification
criteria, particularly as therapeutic strategies in poor-prognosis PsA and
RA are quite similar7. 
LAURA BOGLIOLO, MD; ROBERTO CAPORALI, MD; 
CARLOMAURIZIO MONTECUCCO, MD, Department of
Rheumatology, IRCCS Policlinico S. Matteo, University of Pavia,
Piazzale Golgi 2, 27100 Pavia, Italy.
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Use of Statistical Analysis in Open Extension Studies
To the Editor:
We read the article by Genovese, et al1 with interest. We were surprised
that “no formal statistical comparisons were made among the original 3
treatment groups because of the observational design of the extension
and the fact that the patients’ decision to enter the extension was not
likely to be a random event.” We believe this matter deserves more dis-
cussion.
This paper1 reported a 4-year open experience with 25 mg etanercept
twice a week after a blinded protocol of 10 and 25 mg compared to solo
weekly methotrexate (MTX)2. There was another report about the one-
year outcome, after the blind phase had ended, of a randomized trial3.
This report included formal statistics concerning the data. Do the
authors suggest that the conclusions in the one previous article were
flawed? 
Fortunately this probably was not the case. We rather think the authors’
current statement about randomization being a prerequisite for sound sta-
tistics is incorrect. 
Of course, the authors are correct that data concerning why some
patients chose to participate and others chose not to participate are not fully
available. Nonetheless, concern about bias in different study groups should
not dictate non-performance of statistical analyses, in our opinion. Indeed,
such analyses may help elucidate any bias and help determine whether we
may be dealing with a non-random phenomenon. 
Safety data given in Table 21 suggest that the initial MTX group had
the lowest number of adverse effects. Provision of formal statistical
analyses might have helped readers to determine whether these differ-
ences might be explained by differences in patient status at baseline,
which might have led to conclusions that differed from those of the
authors. 
YUSUF YAZICI, MD, NYU-Hospital for Joint Diseases, New York, NY,
USA; HASAN YAZICI, MD, Istanbul University, Cerrahpasa Medical
Faculty, Istanbul, Turkey. 
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Dr. Genovese, et al reply
To the Editor:
We thank the Drs. Yazici for their response to our article1 and believe that
it offers an excellent forum for understanding the appropriate use of statis-
tical analysis in randomized clinical trials that cross over into longterm
observational studies.
In the 2-year article2 patients had been randomized and remained on their
original treatment assignments for the duration of the 2 years. The blind for
the study was broken during year 2, but on average patients remained blind-
ed for 18.4 months and this study had very low attrition. Safety and efficacy
outcomes were compared between the 3 groups utilizing statistical tests for
significance. This was feasible and appropriate because all groups continued
to receive treatment according to random assignment, and, more important-
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ly, all subjects who received any active drug were included in the analysis.
The analysis in this study used the last observation carried forward (LOCF)
technique to account for missing data and early drop-outs.
The formal longterm extension study began when each patient com-
pleted year 2. In this observational study, all interested subjects were
allowed to receive etanercept at the 25 mg biweekly dose, with the use of
methotrexate (MTX) and corticosteroids determined by the investigator
based on disease activity. The decision to enter the extension was certain-
ly subject to a number of biases. Formal statistical significance testing was
not performed in this study for several reasons: (1) differential drop-out
rates were likely to bias results due to confounding by indication; (2) there
was an increasing amount of heterogeneity of treatment within each group
as other medication changes were made according to disease activity; and
(3) the safety analysis focusing on the use of etanercept examined all
patients who received at least 1 dose of etanercept, and excluded patients
from the MTX arm who did not enter into the etanercept only phase of the
study.
Table 21 shows the safety data for all patients who received at least
one dose of etanercept. Careful examination of subjects included in this
portion of safety analysis shows that only 143 of the original 217 sub-
jects (66%) randomized to the MTX arm received any etanercept due to
early termination from the original phase of the study or elected not to
participate in the longterm extension. In comparison, all subjects origi-
nally assigned to receive either dose of etanercept (208/208 of 25 mg
etanercept and 207/207 of 10 mg etanercept) are included in the safety
analysis. So although it appears that there may be fewer adverse events
in the original MTX arm, fewer subjects were included. Many of the
adverse events seen in the early phases of the study in subjects receiv-
ing MTX without etanercept were not evaluated in the analysis of safe-
ty in subjects receiving etanercept. Inferential statistics in this instance
would be inappropriate because one arm is deliberately left-censored.
The 3 groups in comparison were not equal with respect to length of
time receiving etanercept or with period of time under study. We were
concerned that the inclusion of formal statistics would not only be
unable to uncover any inherent biases, but would lead to misinterpreta-
tions of the data. In fact the application of statistical analysis in this sit-
uation would ignore or obscure the fact these significant biases exist and
would legitimize this type of analysis in the eyes of many readers. While
testing for statistical significance is very important in evaluating study
results, careful attention to the composition of each group and the clini-
cal significance of the measured outcomes should not be ignored in the
absence of p values.
MARK C. GENOVESE, MD, Division of Rheumatology, Stanford
University Medical Center, Palo Alto, California; JOAN M. BATHON, MD,
Division of Rheumatology, Johns Hopkins University, Baltimore,
Maryland; ROY M. FLEISCHMANN, MD, Division of Rheumatology,
University of Texas Southwestern Medical Center at Dallas, Dallas,
Texas; LARRY W. MORELAND, MD, Clinical Immunology and
Rheumatology, University of Alabama at Birmingham, Birmingham,
Alabama; RICHARD W. MARTIN, MD, College of Human Medicine,
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Macrophage Activation Syndrome as an Early Presentation
of Lupus
To the Editor:
We describe the occurrence of macrophage activation syndrome (MAS) as
a presenting feature of childhood systemic lupus erythematosus (SLE).
MAS, a life-threatening complication of systemic inflammatory disorders,
can be difficult to diagnose, despite recognized clinical features1. MAS
associated with lupus is rare in pediatrics, with only one other case report-
ed within a series of 24 children2.
A 10-year-old girl from Yemen presented with a 6 week history of per-
sistent fevers (up to 40°C) and rigors, preceded by 4 months’ weight loss,
anorexia, and lethargy. Questioning revealed symptoms of alopecia,
swollen glands, headaches, and diarrhea. Infection screening was negative,
and fever was unresponsive to antipyretics or broad-spectrum antibiotics.
She was acutely unwell, cachexic, clinically anemic, and had a gallop
rhythm, soft systolic murmur (from hyperdynamic circulation and anemia),
bilateral periorbital edema, and hepatosplenomegaly. She developed sud-
den loss of right-side vision over a period of a few hours.
Investigations showed pancytopenia (hemoglobin 5.5 g/dl, white cell
count 0.9 × 109/l, platelet count 40 × 109/l), positive antinuclear antibodies
(ANA; 1:2560) and anti-dsDNA (25.9 IU/ml; normal < 9.9), and negative
anti-ENA antibodies. Despite a normal bone marrow locally, a repeat aspi-
rate revealed active hemophagocytosis. Diagnosis of MAS was supported
by high lactate dehydrogenase (LDH; 1289–2343 U/l), high ferritin
(1589–2087 µg/l), low fibrinogen (1.0 g/l), low platelet count (40 × 109/l),
and relatively low erythrocyte sedimentation rate (ESR; 30–65 mm/h) dis-
proportionate to the clinical picture (Table 1).
The American Rheumatism Association criteria of lupus were met by
evidence of nephritis (urine albumin/creatinine ratio 77.8 mg/mmol (normal
0.7–7.4), with cellular casts on microscopy, and calculated glomerular fil-
tration rate of 50 ml/min/1.73 m2), cytopenia, positive immunoserology,
positive ANA, and positive antiphospholipid antibodies [aPL; anticardi-
olipin IgG 32.6 U/ml (normal 0–17 U/ml)]. Anti-ß2-glycoprotein and
antiprothrombin were not available. Lupus anticoagulant testing was nega-
tive by dilute Russell viper venom time. Diagnosis was supported by low
complement C3 (0.23 g/l; normal 0.75–1.65), C4 (0.07 g/l; normal
0.14–0.54), and normal C-reactive protein. Renal biopsy (taken 3 weeks
after aggressive treatment) showed glomerular deposition of C1q and C3 on
immunohistochemical staining, with mesangial and subepithelial deposits
on electron microscopy, consistent with WHO class 2 lupus nephritis.
Initial treatment was dexamethasone 10 mg/m2/day (equivalent to 53
mg/day prednisolone), without improvement. Following a rheumatology
referral, her steroid regime was changed to our usual practice of 30
mg/kg/day intravenous methylprednisolone (equivalent to 480 mg pred-
nisolone/day) for 3 consecutive days, repeated 1 week later, with daily
prednisolone maintenance. She remained extremely unwell and was given
further methylprednisolone, together with plasma exchange and intra-
venous cyclophosphamide (500 mg/m2; National Institutes of Health
regime for 6 months, with accelerated dosing at onset). Aspirin was started
owing to positive aPL.
Right side central retinal artery and vein occlusion was identified by
ophthalmologic examination and magnetic resonance image scan (angio-
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graphy and Doppler imaging were unavailable). Thrombophilia screening
was unremarkable, and rate of funduscopy improvement over time was
thought to be consistent with vasculitis rather than thrombosis, so warfarin
was not given. Right side blindness persisted, possibly secondary to neu-
ronal damage.
The clinical course was complicated by acute pancreatitis (diagnosed
by computer tomography scan plus elevated amylase and lipase), a recog-
nized complication of SLE3. She responded to conservative treatment with
antibiotics, steroid, octreotide, and total parenteral nutrition.
MAS represents clinical and laboratory features mediated by cytokine
overproduction from excessive activation and proliferation of well differ-
entiated macrophages (histiocytes)1,4. The striking bone marrow appear-
ance has led to the term “reactive hemophagocytic lymphohistiocytosis”
(HLH) among hematology-oncology investigators4.
Detection of MAS secondary to lupus is complicated, since many fea-
tures are common to both pathologies, such as fever, pancytopenia,
leukopenia, lymphadenopathy, neurological manifestations, arthritis, rash,
hepatomegaly, renal or cardiac manifestations, and increased LDH.
However, hallmark features of MAS include hyperferritinemia, hypofib-
rinoginemia, liver dysfunction with hypertriglyceridemia and raised liver
enzymes, splenomegaly, and bone marrow aspirate showing active hemo-
phagocytosis. A paradoxically low ESR (secondary to hypofibrinoginemia)
in a patient is suggestive1,2,5. Lupus patients with pancytopenia should
have a bone marrow biopsy to exclude MAS. An infection screen is also
necessary, but frequently negative, suggesting lupus related immune
changes as a cause of MAS5.
It is crucial to recognize and treat MAS promptly with immunosup-
pression, and where appropriate, treatment of infection and removal of trig-
gering medications2. There are no agreed protocols, but primary treatment
involves parenteral administration of high-dose corticosteroids with sup-
portive management of fluid balance and coagulopathy1,2,6. Other reported
therapies (most commonly used in conjunction with steroid) include
cyclosporin A, etoposide, intravenous immunoglobulins, cyclophos-
phamide, plasma exchange, and etanercept1,2,6. Etoposide can induce bone
marrow aplasia, and there was reluctance to use cyclosporine due to renal
impairment in this case6. Cyclophosphamide is a recognized treatment of
severe lupus, and was felt to be most appropriate. In view of its delayed
action, with a 10-day nadir, plasma exchange was also used.
The combination of methylprednisolone, plasma exchange, and
cyclophosphamide led to resolution of MAS. This case illustrates the
importance of considering the underlying diagnosis when directing treat-
ment, to halt stimulation of macrophages and prevent mortality.
LIZA J. McCANN, MRCP, BSc, MMedSc, SpR, Clinical Research Fellow,
Great Ormond Street Hospital and Institute of Child Health,
Rheumatology Unit, Philip Ulmann Wing, 30 Guilford Street, London,
WC1N 1EH, UK; NATHAN HASSON, MB, ChB, FRCPCH, Consultant
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Table 1. Investigation results over time related to clinical course (dates shown on top line).
Dec 2 Dec 9 Dec 12 Dec 15 Dec 16 Dec 18 Dec 19 Dec 23 Dec 24 Dec 27 Jan 2 Jan 6 Jan 8 Jan 19 Jan 30
Bone Blood & Dex Dex Day IV MP IV MP Plas Ex. Plas Ex Next Line Renal CYC CYC
marrow. plt given started. 4 Day 1 Day 3. CYC Day 5 course sepsis Bx dose 2 dose 3
Loss of 2nd Pan- Bleed. dose 1 of IV MP
vision bone creatitis. Plas Ex given
Clinical R eye marrow. Plt
Event/ Normal Blood given
Investigation Range given
Hb 11.5–15.5 g/dl 7.5 5.5 8.9 10.4 9.3 6 12.2 8.4 7.9 10.5 10 9.4 10.7 9.3 9.6
WCC 4.5–13.5 × 109/l 1.6 0.89 1.8 3.94 6.09 10.39 11.18 5.65 5.09 1.96 1.22 5.39 6.05 10.49 17.84
Neutrophils 1.5–8.0 × 109/l 0.8 0.59 0.92 2.28 4.74 8.61 9.22 4.85 4.38 1.46 0.54 3.9 4.26 8.02 13.02
Lymphocytes 1.5–7.0 × 109/l 0.6 0.23 0.67 0.82 0.68 0.64 0.96 0.52 0.51 0.32 0.19 0.75 0.87 1.52 2.14
Platelets 150–450 × 109/l 83 40 70 45 49 120 92 53 52 72 127 131 112 260 291
ESR 0–10 mm/h 31 40 35 80 8 3 65 30
CRP < 20 mg/l < 7 < 7 < 7 8 38 37 < 7
PT 9.9–12.5 s 11.4 11 12.5 15.5 11.8 10.3
APTT 26–38 s 47.2 45.1 33.4 34.8 37.8 33.2
Thrombin 9.2–15.0 s 18.6 16.4 19 19.2 11.2 11.7
Fibrinogen 1.7–4.0 g/l 1.1 1.4 1 0.7 1.6 3.6
Ferritin 7–150 µg/l 2087 1589
Urea 2.5–6.0 mmol/l 1.8 4.7 4.3 11.6 10 10.4 10.8 16 16.8 14.4 5.5 5.4 6.8 8.9 8.6
Creatinine 35–70 µmol/l 51 54 59 79 65 72 59 51 44 48 36 34 36 39 38
ALP 130–560 U/l 123 119 111 82 83 71 37 33 33 49 59 6 8 75 86
ALT 10–35 U/l 44 54 49 33 29 26 23 22 18 7 28 73 36 28 24
Amylase 30–100 U/l 27 1020 207 118 98 85 62 76 84 61
Lipase 13–150 IU/l > 10000 1280 915 779 640 354 150 79
LDH 380–770 U/l 1289 2343
Dex: dexamethasone, CYC: cyclophosphamide, Plas Ex: plasma exchange, IV MP: intravenous methylprednisolone, plt: platelet transfusion, Bx: biopsy, Hb:
hemoglobin, WCC: white blood cell count, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, PT: prothrombin time, APTT: activated partial
thromboplastin time, LDH: lactate dehydrogenase.
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Corrections
Tannenbaum H, Bombardier C, Davis P, Russell AS. An
evidence-based approach to prescribing nonsteroidal 
antiinflammatory drugs. Third Canadian Consensus
Conference. J Rheuamtol 2006;33:140-57. The penultimate
sentence of the “Lumiracoxib” section on page 143 should
read: “Importantly, however, taking ASA largely negated
the GI benefits of lumiracoxib, with reduction in complica-
tions by [not “to”] only 21%.” We regret the error.
Wakefield RJ, Balint PV, Szkudlarek M, et al.
Musculoskeletal ultrasound including definitions for ultra-
sonographic pathology. J Rheumatol 2005;32:2485-7.
Author’s name George Bruyn should be George A.W.
Bruyn. We regret the error.
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